Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1493) 1493
Publication (80) 80
Book Review (5) 5
Magazine Article (3) 3
Newsletter (3) 3
Newspaper Article (2) 2
Book Chapter (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1222) 1222
male (872) 872
female (840) 840
antineoplastic combined chemotherapy protocols - therapeutic use (717) 717
lomustine - administration & dosage (702) 702
lomustine - therapeutic use (649) 649
middle aged (645) 645
adult (617) 617
oncology (441) 441
aged (433) 433
vincristine - administration & dosage (399) 399
brain neoplasms - drug therapy (358) 358
chemotherapy (350) 350
combined modality therapy (304) 304
animals (270) 270
procarbazine - administration & dosage (268) 268
index medicus (265) 265
lomustine (261) 261
adolescent (259) 259
cyclophosphamide - administration & dosage (230) 230
drug therapy, combination (218) 218
treatment outcome (217) 217
prognosis (212) 212
antineoplastic agents - therapeutic use (207) 207
antineoplastic combined chemotherapy protocols - adverse effects (195) 195
lung neoplasms - drug therapy (194) 194
vincristine - therapeutic use (190) 190
doxorubicin - administration & dosage (182) 182
radiotherapy (180) 180
lomustine - adverse effects (177) 177
nitrosourea compounds - therapeutic use (171) 171
cancer (160) 160
clinical neurology (152) 152
clinical trials as topic (151) 151
glioma - drug therapy (140) 140
mice (140) 140
child (138) 138
time factors (137) 137
brain neoplasms - radiotherapy (135) 135
methotrexate - administration & dosage (131) 131
survival (129) 129
hodgkin disease - drug therapy (127) 127
survival analysis (126) 126
survival rate (126) 126
cyclophosphamide - therapeutic use (125) 125
dacarbazine - administration & dosage (125) 125
prednisone - administration & dosage (123) 123
procarbazine - therapeutic use (122) 122
brain neoplasms - pathology (121) 121
follow-up studies (121) 121
neoplasm staging (118) 118
cisplatin - administration & dosage (116) 116
retrospective studies (116) 116
temozolomide (116) 116
etoposide - administration & dosage (113) 113
glioblastoma - drug therapy (112) 112
bleomycin - administration & dosage (111) 111
drug administration schedule (109) 109
carcinoma, small cell - drug therapy (106) 106
brain neoplasms - therapy (105) 105
doxorubicin - therapeutic use (104) 104
disease-free survival (102) 102
dose-response relationship, drug (101) 101
antineoplastic combined chemotherapy protocols - administration & dosage (98) 98
ccnu (98) 98
child, preschool (97) 97
vincristine (96) 96
prospective studies (95) 95
antineoplastic agents, alkylating - therapeutic use (94) 94
carmustine - therapeutic use (94) 94
dacarbazine - therapeutic use (94) 94
melanoma - drug therapy (94) 94
glioblastoma (93) 93
gliomas (93) 93
therapy (93) 93
vinblastine - administration & dosage (91) 91
brain neoplasms - mortality (90) 90
procarbazine (89) 89
veterinary sciences (86) 86
neoplasm metastasis (85) 85
dogs (84) 84
tumors (84) 84
neoplasm recurrence, local - drug therapy (83) 83
remission induction (83) 83
medicine & public health (81) 81
methotrexate - therapeutic use (81) 81
chemotherapy, adjuvant (80) 80
drug evaluation (80) 80
radiation-therapy (79) 79
astrocytoma - drug therapy (74) 74
dacarbazine - analogs & derivatives (74) 74
care and treatment (73) 73
antineoplastic agents - administration & dosage (72) 72
lung neoplasms - mortality (71) 71
oligodendroglioma - drug therapy (70) 70
radiotherapy dosage (68) 68
brain neoplasms - surgery (67) 67
glioma (65) 65
neoplasm recurrence, local (62) 62
surgery (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1318) 1318
German (46) 46
French (39) 39
Russian (37) 37
Polish (17) 17
Chinese (11) 11
Italian (10) 10
Spanish (10) 10
Japanese (9) 9
Croatian (1) 1
Czech (1) 1
Hungarian (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Anti-angiogenic therapy for high-grade glioma
by Ameratunga, Malaka and Pavlakis, Nick and Wheeler, Helen and Grant, Robin and Simes, John and Khasraw, Mustafa
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2018, Volume 2018, Issue 11, p. CD008218
Background This is an updated version of the original Cochrane Review published in September 2014. The most common primary brain tumours in adults are gliomas.... 
MEDICINE, GENERAL & INTERNAL | STANDARD TREATMENT | RECURSIVE PARTITIONING ANALYSIS | NEWLY-DIAGNOSED GLIOBLASTOMA | RANDOMIZED PHASE-III | SINGLE-AGENT BEVACIZUMAB | BEVACIZUMAB PLUS IRINOTECAN | CENTRAL-NERVOUS-SYSTEM | OPEN-LABEL | QUALITY-OF-LIFE | ADJUVANT TEMOZOLOMIDE | Neovascularization, Pathologic - mortality | Bevacizumab - therapeutic use | Snake Venoms - therapeutic use | Dacarbazine - therapeutic use | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Brain Neoplasms - blood supply | Irinotecan - therapeutic use | Temozolomide - therapeutic use | Proteinuria - chemically induced | Hypertension - chemically induced | Dacarbazine - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Lomustine - therapeutic use | Brain Neoplasms - mortality | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Brain Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Neovascularization, Pathologic - drug therapy | Progression-Free Survival | Glioblastoma - drug therapy | Glioblastoma - blood supply | Glioblastoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
by Wick, Wolfgang and Roth, Patrick and Hartmann, Christian and Hau, Peter and Nakamura, Makoto and Stockhammer, Florian and Sabel, Michael C and Wick, Antje and Koeppen, Susanne and Ketter, Ralf and Vajkoczy, Peter and Eyupoglu, Ilker and Kalff, Rolf and Pietsch, Torsten and Happold, Caroline and Galldiks, Norbert and Schmidt-Graf, Friederike and Bamberg, Michael and Reifenberger, Guido and Platten, Michael and Von Deimling, Andreas and Meisner, Christoph and Wiestler, Benedikt and Weller, Michael and German Canc Soc and Neurooncology Working Group (NOA) of the German Cancer Society
Neuro-Oncology, ISSN 1522-8517, 11/2016, Volume 18, Issue 11, pp. 1529 - 1537
Background. Optimal treatment and precise classification for anaplastic glioma are needed. Methods. The objective for long-term follow-up of NOA-04 is to... 
1p/19q | Anaplastic gliomas | MGMT | CIMP | SURVIVAL | OLIGODENDROGLIOMA | ASTROCYTOMAS | ATRX | MGMT PROMOTER METHYLATION | CLASSIFICATION | PROCARBAZINE | TUMORS | CLINICAL NEUROLOGY | anaplastic gliomas | ONCOLOGY | DIFFUSE | AGE | Glioma - diagnosis | Dacarbazine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Glioma - radiotherapy | Young Adult | Dacarbazine - analogs & derivatives | Adult | Female | Lomustine - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Brain Neoplasms - radiotherapy | Chemoradiotherapy - methods | Brain Neoplasms - diagnosis | Treatment Outcome | Brain Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Aged | Temozolomide | Glioma - drug therapy | 19q | Clinical Investigation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Antiangiogenic therapy for high-grade glioma
by Khasraw, Mustafa and Khasraw, Mustafa and Ameratunga, Malaka S and Ameratunga, Malaka S and Grant, Robin and Grant, Robin and Wheeler, Helen and Wheeler, Helen and Pavlakis, Nick and Pavlakis, Nick
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 9, Issue 9, pp. CD008218 - CD008218
Background The most common primary brain tumours in adults are gliomas. Gliomas span a spectrum from low to high-grade and are graded pathologically on a scale... 
MALIGNANT GLIOMA | MEDICINE, GENERAL & INTERNAL | RECURSIVE PARTITIONING ANALYSIS | BEVACIZUMAB | NEWLY-DIAGNOSED GLIOBLASTOMA | PHASE-III | RANDOMIZED-TRIAL | RADIOTHERAPY | RESPONSE ASSESSMENT CRITERIA | RADIATION-THERAPY | TEMOZOLOMIDE | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Snake Venoms - therapeutic use | Dacarbazine - therapeutic use | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Brain Neoplasms - blood supply | Brain Neoplasms - drug therapy | Bevacizumab | Randomized Controlled Trials as Topic | Proteinuria - chemically induced | Neovascularization, Pathologic - drug therapy | Hypertension - chemically induced | Dacarbazine - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Lomustine - therapeutic use | Brain Neoplasms - mortality | Glioblastoma - drug therapy | Angiogenesis Inhibitors - adverse effects | Glioblastoma - blood supply | Glioblastoma - mortality | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
by Bent, M.J. van den and Dubbink, H.J and Marie, Y and Brandes, A.A and Taphoorn, M.J.B and Wesseling, P and Frenay, M and Tijssen, C.C and Lacombe, D and Idbaih, A and Marion, R. van and Kros, J.M and Dinjens, W.N and Gorlia, T and Sanson, M
Clinical Cancer Research, ISSN 1078-0432, 2010, Volume 16, Issue 5, pp. 1597 - 1604
PURPOSE: Recent studies have shown the prognostic significance of IDH1 mutations in glioma. It is yet unclear if IDH1 mutations are predictive for outcome to... 
GLIOMAS | PROMOTER HYPERMETHYLATION | GLIOBLASTOMAS | ONCOLOGY | CODON 132 MUTATION | OLIGOASTROCYTOMAS | Prognosis | Oligodendroglioma - genetics | Humans | Middle Aged | DNA Repair Enzymes - genetics | Male | Young Adult | Tumor Suppressor Proteins - genetics | Polymerase Chain Reaction | Adult | Female | Lomustine - therapeutic use | Brain Neoplasms - mortality | Oligodendroglioma - mortality | Promoter Regions, Genetic | Kaplan-Meier Estimate | Brain Neoplasms - genetics | In Situ Hybridization, Fluorescence | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Combined Modality Therapy | Radiotherapy | Disease-Free Survival | DNA Modification Methylases - genetics | Genes, erbB-1 | Oligodendroglioma - therapy | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Brain Neoplasms - therapy | Vincristine - therapeutic use | Aged | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
by Gregory Cairncross and Brian Berkey and Edward Shaw and Robert Jenkins and Bernd Scheithauer and David Brachman and Jan Buckner and Karen Fink and Luis Souhami and Normand Laperierre and Minesh Mehta and Walter Curran and Intergroup Radiation Therapy Oncology Group Trial 9402
Journal of Clinical Oncology, ISSN 0732-183X, 06/2006, Volume 24, Issue 18, pp. 2707 - 2714
Purpose Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (BT) at diagnosis, but they also... 
MALIGNANT GLIOMA | SURVIVAL | ONCOLOGY | OLIGOASTROCYTOMAS | CHROMOSOME ARMS 1P | 19Q | TUMORS | DELETIONS | TEMOZOLOMIDE | Oligodendroglioma - surgery | Oligodendroglioma - genetics | Humans | Middle Aged | Male | Loss of Heterozygosity | Oligodendroglioma - radiotherapy | Brain Neoplasms - surgery | Chromosomes, Human, Pair 1 | Adult | Dose Fractionation | Female | Lomustine - therapeutic use | Chemotherapy, Adjuvant | Brain Neoplasms - radiotherapy | Oligodendroglioma - drug therapy | Proportional Hazards Models | Radiotherapy, High-Energy | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Chromosomes, Human, Pair 19 | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
by Martin J. van den Bent and Antoine F. Carpentier and Alba A. Brandes and Marc Sanson and Martin J.B. Taphoorn and Hans J.J.A. Bernsen and Marc Frenay and Cees C. Tijssen and Wolfgang Grisold and Laslo Sipos and Hanny Haaxma-Reiche and Johannes M. Kros and Mathilde C.M. van Kouwenhoven and Charles J. Vecht and Anouk Allgeier and Denis Lacombe and Thierry Gorlia
Journal of Clinical Oncology, ISSN 0732-183X, 06/2006, Volume 24, Issue 18, pp. 2715 - 2722
Purpose Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled... 
GLIOMAS | GLIOBLASTOMA | RADIOTHERAPY | TUMORS | UMCG Approved | CHEMOTHERAPY | TEMOZOLOMIDE | ONCOLOGY | Oligodendroglioma - genetics | Humans | Middle Aged | Brain Neoplasms - genetics | Male | Brain Neoplasms - drug therapy | Loss of Heterozygosity | Oligodendroglioma - radiotherapy | Chromosomes, Human, Pair 19 | Chromosomes, Human, Pair 1 | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Adult | Dose Fractionation | Female | Lomustine - therapeutic use | Aged | Chemotherapy, Adjuvant | Brain Neoplasms - radiotherapy | Oligodendroglioma - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Therapeutic options for recurrent malignant glioma
by Niyazi, Maximilian and Siefert, Axel and Schwarz, Silke Birgit and Ganswindt, Ute and Kreth, Friedrich-Wilhelm and Tonn, Jörg-Christian and Belka, Claus
Radiotherapy and Oncology, ISSN 0167-8140, 2010, Volume 98, Issue 1, pp. 1 - 14
Abstract Background and purpose: Despite the given advances in neuro-oncology most patients with high grade malignant glioma ultimately fail locally or... 
Hematology, Oncology and Palliative Medicine | Malignant glioma | Relapse | Temozolomide | Radiotherapy | Bevacizumab | PROGNOSTIC-FACTORS | FRACTIONATED STEREOTACTIC RADIOSURGERY | BEVACIZUMAB PLUS IRINOTECAN | DI-NEURO-ONCOLOGIA | INTERSTITIAL PHOTODYNAMIC THERAPY | ANAPLASTIC ASTROCYTOMA | PHASE-II TRIAL | ONCOLOGY | BRAIN-TUMOR CONSORTIUM | TEMOZOLOMIDE-REFRACTORY GLIOBLASTOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | HIGH-GRADE GLIOMA | Radiotherapy Dosage | Humans | Neoplasm Recurrence, Local - therapy | Brain Neoplasms - therapy | Glioma - therapy | Radiosurgery | Salvage Therapy | Angiogenesis Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Brachytherapy | Care and treatment | Phosphatases | Radioisotope brachytherapy | Mortality | Etoposide | Photochemotherapy | Chemotherapy | Cyclophosphamide | Gliomas | Analysis | Lomustine | Vascular endothelial growth factor | Health aspects | Growth factors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
by Brandes, Alba A and Carpentier, Antoine F and Kesari, Santosh and Sepulveda-Sanchez, Juan M and Wheeler, Helen R and Chinot, Olivier and Cher, Lawrence and Steinbach, Joachim P and Capper, David and Specenier, Pol and Rodon, Jordi and Cleverly, Ann and Smith, Claire and Gueorguieva, Ivelina and Miles, Colin and Guba, Susan C and Desaiah, Durisala and Lahn, Michael M and Wick, Wolfgang
Neuro-Oncology, ISSN 1522-8517, 08/2016, Volume 18, Issue 8, pp. 1146 - 1156
The combination of galunisertib, a transforming growth factor (TGF)-beta receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in... 
Antitumor activity | Galunisertib monohydrate (LY2157299) | Bayesian design | Safety | Pharmacokinetics | Phase II randomized study | SURVIVAL | CELLS | DIAGNOSIS | TGF-BETA | KINASE INHIBITOR | CLINICAL NEUROLOGY | INHIBITOR LY2157299 MONOHYDRATE | ONCOLOGY | antitumor activity | safety | GROWTH | pharmacokinetics | galunisertib monohydrate (LY2157299) | ASSOCIATION | Pyrazoles - therapeutic use | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Brain Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Quinolines - pharmacokinetics | Disease-Free Survival | Drug Therapy, Combination - adverse effects | Drug Therapy, Combination - methods | Lomustine - pharmacokinetics | Female | Lomustine - therapeutic use | Quinolines - therapeutic use | Antineoplastic Agents, Alkylating - adverse effects | Glioblastoma - drug therapy | Pyrazoles - pharmacokinetics | Quinolines - adverse effects | Pyrazoles - adverse effects | Clinical Investigations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma
by Wick, Wolfgang and Fricke, Harald and Junge, Klaus and Kobyakov, Grigory and Martens, Tobias and Heese, Oliver and Wiestler, Benedikt and Schliesser, Maximilian G and Von Deimling, Andreas and Pichler, Josef and Vetlova, Elena and Harting, Inga and Debus, Jüurgen and Hartmann, Christian and Kunz, Claudia and Platten, Michael and Bendszus, Martin and Combs, Stephanie E
Clinical Cancer Research, ISSN 1078-0432, 12/2014, Volume 20, Issue 24, pp. 6304 - 6313
Purpose: Preclinical data indicate anti-invasive activity of APG101, a CD95 ligand (CD95L)-binding fusion protein, in glioblastoma. Experimental Design:... 
TRIAL | CELLS | CD95 | INVASION | RECURRENT MALIGNANT GLIOMA | EFFICACY | ONCOLOGY | LOMUSTINE | TOLERABILITY | COMBINATION | TEMOZOLOMIDE | fas Receptor - administration & dosage | Prognosis | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Glioblastoma - radiotherapy | Young Adult | Antineoplastic Agents - adverse effects | Adult | Female | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Immunoglobulin G - therapeutic use | Treatment Outcome | Combined Modality Therapy | Tumor Burden | fas Receptor - adverse effects | fas Receptor - therapeutic use | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Glioblastoma - pathology | Biomarkers | Quality of Life | Aged | Glioblastoma - drug therapy | Glioblastoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma
by Duerinck, J and Du Four, S and Vandervorst, F and D’Haene, N and Le Mercier, M and Michotte, A and Van Binst, A M and Everaert, H and Salmon, I and Bouttens, F and Verschaeve, V and Neyns, B
Journal of Neuro-Oncology, ISSN 0167-594X, 5/2016, Volume 128, Issue 1, pp. 147 - 155
We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule... 
Neurology | Medicine & Public Health | Glioblastoma | Oncology | Axitinib | Recurrent | Bevacizumab | Bevacizumab - therapeutic use | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Positron-Emission Tomography | Protein Kinase Inhibitors - adverse effects | Young Adult | Glioblastoma - diagnostic imaging | Glioblastoma - genetics | Neoplasm Recurrence, Local - diagnostic imaging | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Lomustine - therapeutic use | Steroids - therapeutic use | Imidazoles - therapeutic use | Radiopharmaceuticals | Angiogenesis Inhibitors - adverse effects | Imidazoles - adverse effects | Brain Neoplasms - genetics | Treatment Outcome | Brain Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Fluorodeoxyglucose F18 | Neoplasm Recurrence, Local - genetics | Aged | Indazoles - adverse effects | Glioblastoma - drug therapy | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Medical research | Care and treatment | Relapse | Corticosteroids | Endothelial growth factors | Physicians | Clinical trials | Medicine, Experimental | Glioblastoma multiforme | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
by Wolfgang Wick and Vinay K. Puduvalli and Marc C. Chamberlain and Martin J. van den Bent and Antoine F. Carpentier and Lawrence M. Cher and Warren Mason and Michael Weller and Shengyan Hong and Luna Musib and Astra M. Liepa and Donald E. Thornton and Howard A. Fine
Journal of Clinical Oncology, ISSN 0732-183X, 03/2010, Volume 28, Issue 7, pp. 1168 - 1174
Purpose This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).... 
MALIGNANT GLIOMA | TRIAL | PROTEIN-KINASE-C | THERAPY | ONCOLOGY | MULTIFORME | CANCER | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | BRAIN-TUMORS | TEMOZOLOMIDE | Humans | Lomustine - adverse effects | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Brain Neoplasms - drug therapy | Indoles - adverse effects | Adult | Female | Indoles - pharmacokinetics | Indoles - therapeutic use | Lomustine - therapeutic use | Aged | Brain Neoplasms - mortality | Glioblastoma - drug therapy | Glioblastoma - mortality | Index Medicus | Neur6 | Original Reports | Neur1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Practice changing mature results of RTOG study 9802: Another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma
by Bent, Martin
Neuro-Oncology, ISSN 1522-8517, 01/2014, Volume 16, Issue 12, pp. 1570 - 1574
textabstractThe long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU,... 
Chemotherapy | PCV | Low grade glioma | Temozolomide | temozolomide | RANDOMIZED-TRIAL | VINCRISTINE CHEMOTHERAPY | chemotherapy | COGNITIVE FUNCTION | CLINICAL NEUROLOGY | PHASE-III TRIAL | RECURRENT OLIGODENDROGLIOMA | ONCOLOGY | ANAPLASTIC OLIGODENDROGLIOMA | CLINICAL-TRIALS | TERM-FOLLOW-UP | EUROPEAN-ORGANIZATION | low grade glioma | Humans | Male | Survival Rate | Treatment Outcome | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Chemoradiotherapy, Adjuvant | Glioma - radiotherapy | Clinical Trials, Phase III as Topic | Procarbazine - therapeutic use | Brain Neoplasms - therapy | Glioma - therapy | Vincristine - therapeutic use | Female | Lomustine - therapeutic use | Brain Neoplasms - radiotherapy | Glioma - drug therapy | Index Medicus | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
by Buckner, Jan C and Shaw, Edward G and Pugh, Stephanie L and Chakravarti, Arnab and Gilbert, Mark R and Barger, Geoffrey R and Coons, Stephen and Ricci, Peter and Bullard, Dennis and Brown, Paul D and Stelzer, Keith and Brachman, David and Suh, John H and Schultz, Christopher J and Bahary, Jean-Paul and Fisher, Barbara J and Kim, Harold and Murtha, Albert D and Bell, Erica H and Won, Minhee and Mehta, Minesh P and Curran, Walter J
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 14, pp. 1344 - 1355
Patients with grade 2 glioma were randomly assigned to radiation therapy alone or radiation therapy plus six cycles of chemotherapy. The median overall... 
MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | RECURRENT GLIOMA | THERAPY | ANAPLASTIC OLIGODENDROGLIOMA | LOMUSTINE | TERM-FOLLOW-UP | RADIOTHERAPY | CANCER | CHEMOTHERAPY | Procarbazine - administration & dosage | Astrocytoma - radiotherapy | Oligodendroglioma - mortality | Follow-Up Studies | Humans | Male | Combined Modality Therapy | Brain Neoplasms - drug therapy | Oligodendroglioma - radiotherapy | Young Adult | Disease-Free Survival | Neoplasm Grading | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Astrocytoma - drug therapy | Survival Analysis | Vincristine - administration & dosage | Adult | Female | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Lomustine - administration & dosage | Astrocytoma - mortality | Oligodendroglioma - drug therapy | Procarbazine | Care and treatment | Chemotherapy | Usage | Gliomas | Lomustine | Dosage and administration | Cancer | Brain cancer | Radiation therapy | Oligoastrocytoma | Survival | Patients | Vincristine | Oligodendroglioma | Glioma | Biopsy | Astrocytoma | Tumors
Journal Article
Details down arrow